-- Ready-to-dilute, multi-dose vials reduce compounding time and waste -- BRIDGEWATER, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (€œNevakar€), a biopharmaceutical company...
ROSEMONT, Ill., May 4, 2023 /PRNewswire/ -- Long Grove Pharmaceuticals announced the strategic in-licensing of Norepinephrine in 0.9% Sodium Chloride premix formulation from Nevakar Injectables, Inc. This manufactured, ready-to-use formulation is room-temperature stable and will be available in three commonly administered strengths; 4mg/250mL (16mcg/mL), 8mg/250mL (32mcg/mL), and 16mg/250mL (64mcg/mL), helping strengthen what has historically been a fragile critical care supply chain.
BRIDGEWATER, N.J., May 02, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings. Nevakar announced today that it has entered into an asset sale agreement with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), for the sale of six of its differentiated, sterile injectable product candidates, which are currently in various stages of early development. Under the terms of the agreement, Nevakar transferred all rights and responsibilities for these product candidates to Endo in exchange for an upfront payment of $35 million.
Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use...
BRIDGEWATER, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc. (“Nevakar”), a wholly owned subsidiary of Nevakar, Inc., is a biopharmaceutical company developing multiple sterile...
BRIDGEWATER, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory...
BRIDGEWATER, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it...
BRIDGEWATER, N.J. and CLERMONT-FERRAND, France, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered into an exclusive licensing agreement for the commercialization of NVK-002 in Europe. NVK-002 is a proprietary, investigational, preservative-free eye drop administered nightly and intended for slowing the progression of myopia in children ages three to 17. It is currently under clinical evaluation in the CHAMP (Childhood Atropine for Myopia Progression) study, a Phase III clinical trial being carried out in the U.S. and Europe.
Bridgewater, NJ, October 22, 2020 – Nevakar Inc., a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today it received approval from the U.S. Food and Drug Administration (FDA) to market Ephedrine Sulfate Injection in a ready- to-use 50mg/10 ml single use vial presentation. Under an exclusive licensing agreement with Endo International’s (NASDAQ: ENDP) subsidiary, Endo Ventures Limited, Par Pharmaceuticals’ Sterile Products division will launch and distribute the product. This is the first approval under the previously announced collaboration between Nevakar and Endo for the development of five differentiated, sterile injectable products in the U.S. and Canada. Under the terms of the agreement, Nevakar has responsibility to develop and obtain FDA approval for these products and Par Pharmaceuticals’ Sterile Products division will launch and distribute the products.